secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001104659-24-127231
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS triggers interim analysis in Phase 3 REGAL trial of GPS in AML; IDMC meeting in Jan 2025
--------------------------------------------------------------------------------

- Pre-specified threshold of 60 deaths reached, triggering IDMC interim analysis.
- IDMC to review efficacy, futility, and safety data from the Phase 3 REGAL trial in January 2025.
- GPS is a potential new treatment for acute myeloid leukemia (AML).
- Company hosted a webcast on December 10, 2024, to discuss the milestone and possible outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465924127231/0001104659-24-127231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465924127231/tm2430677d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer